Insider Transactions in Q1 2021 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
812
-13.42%
|
$203,812
$251.88 P/Share
|
|
Mar 30
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
667
-11.76%
|
$167,417
$251.88 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-10.2%
|
$172,437
$251.58 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+25.54%
|
-
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-15.98%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+26.33%
|
-
|
|
Mar 27
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-7.47%
|
$198,290
$251.58 P/Share
|
|
Mar 27
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
2,104
+16.59%
|
-
|
|
Mar 27
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-11.88%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+21.0%
|
-
|
|
Mar 27
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-7.07%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+13.65%
|
-
|
|
Mar 27
2021
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,595
-8.76%
|
$902,345
$251.58 P/Share
|
|
Mar 27
2021
|
Glenn A Eisenberg Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
8,042
+16.39%
|
-
|
|
Feb 18
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+37.95%
|
$355,224
$164.55 P/Share
|
|
Feb 18
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,317
-87.11%
|
$558,397
$241.51 P/Share
|
|
Feb 16
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
188
-2.1%
|
$44,556
$237.06 P/Share
|
|
Feb 16
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
208
-1.51%
|
$49,088
$236.33 P/Share
|
|
Feb 12
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-11.93%
|
$62,594
$238.26 P/Share
|
|
Feb 12
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
867
+27.36%
|
-
|
|
Feb 12
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
873
-2.23%
|
$207,774
$238.26 P/Share
|
|
Feb 12
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,940
+6.59%
|
-
|
|
Feb 12
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
854
-4.2%
|
$203,252
$238.26 P/Share
|
|
Feb 12
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,870
+11.35%
|
-
|
|
Feb 12
2021
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
512
-0.78%
|
$121,856
$238.26 P/Share
|
|
Feb 12
2021
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,720
+2.54%
|
-
|
|
Feb 12
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-1.06%
|
$42,840
$238.26 P/Share
|
|
Feb 12
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
581
+3.32%
|
-
|
|
Feb 12
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
142
-1.58%
|
$33,796
$238.26 P/Share
|
|
Feb 12
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
517
+5.43%
|
-
|
|
Feb 12
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-1.71%
|
$37,604
$238.26 P/Share
|
|
Feb 12
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
573
+5.85%
|
-
|
|
Feb 05
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
203
-4.66%
|
$45,675
$225.85 P/Share
|
|
Feb 05
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
109
-2.52%
|
$24,525
$225.85 P/Share
|
|
Feb 04
2021
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+4.73%
|
-
|
|
Feb 04
2021
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+45.97%
|
-
|
|
Feb 04
2021
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+12.74%
|
-
|
|
Feb 04
2021
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+9.46%
|
-
|
|
Feb 04
2021
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+8.24%
|
-
|
|
Feb 04
2021
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+13.97%
|
-
|
|
Feb 04
2021
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+13.66%
|
-
|
|
Feb 04
2021
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.63%
|
$22,077
$223.78 P/Share
|
|
Feb 04
2021
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+5.92%
|
-
|
|
Feb 04
2021
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
96
-9.51%
|
$21,408
$223.78 P/Share
|
|
Feb 04
2021
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+21.71%
|
-
|
|
Feb 04
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
131
-1.2%
|
$29,213
$223.78 P/Share
|
|
Feb 04
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
373
+3.3%
|
-
|
|
Feb 04
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
190
-3.92%
|
$42,370
$223.78 P/Share
|
|
Feb 04
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+10.37%
|
-
|
|
Feb 04
2021
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
306
-0.95%
|
$68,238
$223.78 P/Share
|